Tuesday, 6 October 2026European Markets

AKER SOLUTIONS Stock Rises By 16% In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of AKER SOLUTIONS (Oslo Børs All-share Index_GI: AKSO.OL) jumped by a staggering 16.25% in 5 sessions from 38.02 kr to 44.20 kr at 19:25 EST on Friday, after two successive sessions in a row of gains. Oslo Børs All-share Index_GI is rising 0.37% to 1,418.24 kr, after three sequential sessions in a row of losses.

About AKER SOLUTIONS

Aker Solutions ASA provides solutions, products, systems, and services to the oil and gas industry worldwide. It offers field planning, feasibility, and concept studies; specialist engineering, project management, and procurement services; floater designs, offshore wind, as well as engages in design, delivery, and construction of deepwater risers, oil, and gas production, and receiving and processing facilities. In addition, the company provides offshore fish farming, carbon capture, utilization and storage, hydrogen, and offshore wind solutions. Further, the company designs and constructs jackets for construction services and offers electrification services. Additionally, the company provides subsea production, compression, pump, power distribution, and processing systems, and subsea lifecycle services. Furthermore, the company offers maintenance, modifications, decommissioning, asset integrity management, hook-up, and completion solutions. Aker Solutions ASA was founded in 1841 and is headquartered in Fornebu, Norway.

Earnings Per Share

As for profitability, AKER SOLUTIONS has a trailing twelve months EPS of -3.13 kr.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AKER SOLUTIONS's stock is considered to be oversold (<=20).

Volume

Today's last reported volume for AKER SOLUTIONS is 1029456 which is 23.54% below its average volume of 1104420.

More news about AKER SOLUTIONS (AKSO.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com